7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Nociplastic pain is defined as pain due to sensitization of the nervous system, without a sufficient underlying anatomical abnormality to explain the severity of pain. Nociplastic pain may be manifest in various organ systems, is often perceived as being more widespread rather than localized and is commonly associated with central nervous system symptoms of fatigue, difficulties with cognition and sleep, and other somatic symptoms; all features that contribute to considerable suffering. Exemplified by fibromyalgia, nociplastic conditions also include chronic visceral pain, chronic headaches and facial pain, and chronic musculoskeletal pain. It has been theorized that dysfunction of the endocannabinoid system may contribute to persistent pain in these conditions. As traditional treatments for chronic pain in general and nociplastic pain in particular are imperfect, there is a need to identify other treatment options. Cannabis-based medicines and medical cannabis (MC) may hold promise and have been actively promoted by the media and advocacy. The medical community must be knowledgeable of the current evidence in this regard to be able to competently advise patients. This review will briefly explain the understanding of nociplastic pain, examine the evidence for the effect of cannabinoids in these conditions, and provide simplified guidance for healthcare providers who may consider prescribing cannabinoids for these conditions.

          Related collections

          Author and article information

          Journal
          Drugs
          Drugs
          Springer Science and Business Media LLC
          1179-1950
          0012-6667
          Dec 2021
          : 81
          : 18
          Affiliations
          [1 ] Alan Edwards Pain Management Unit, Division of Rheumatology, Health Centre Montreal, McGill University, Montreal, QC, Canada. Mary-Ann.Fitzcharles.med@ssss.gouv.qc.ca.
          [2 ] Division of Rheumatology, Montreal General Hospital, McGill University Health Centre, 1650 Cedar Ave, Montreal, QC, H3G 1A4, Canada. Mary-Ann.Fitzcharles.med@ssss.gouv.qc.ca.
          [3 ] Pain Medicine, Department of Anesthesiology, University Medical Center Göttingen, Göttingen, Germany.
          [4 ] Department of Neurology, Technische Universität München, Munich, Germany.
          [5 ] Department Psychosomatic Medicine and Psychotherapy, Technische Universität München, Munich, Germany.
          [6 ] Health Care Center for Pain Medicine, and Mental Health Saarbrücken, Saarbrücken, Germany.
          Article
          10.1007/s40265-021-01602-1
          10.1007/s40265-021-01602-1
          34800285
          0c9b104f-4902-4e5e-acba-d8a5e2b7cd1e
          © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
          History

          Comments

          Comment on this article